Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study.
- DOI
- 10.1016/j.breast.2022.03.001
- Published
- 2022 Aug
- Container
- Breast (Edinburgh, Scotland)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.breast.2022.03.001,
title = {Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study.},
author = {Gligorov J and Pivot X and Ataseven B and De Laurentiis M and Jung KH and Manikhas A and Abdel Azim H and Gupta K and Alexandrou A and Herraez-Baranda L and Tosti N and Restuccia E},
year = {2022},
journal = {Breast (Edinburgh, Scotland)},
doi = {10.1016/j.breast.2022.03.001},
url = {https://doi.org/10.1016/j.breast.2022.03.001}
}RIS
TY - JOUR TI - Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study. AU - Gligorov J AU - Pivot X AU - Ataseven B AU - De Laurentiis M AU - Jung KH AU - Manikhas A AU - Abdel Azim H AU - Gupta K AU - Alexandrou A AU - Herraez-Baranda L AU - Tosti N AU - Restuccia E PY - 2022 JO - Breast (Edinburgh, Scotland) DO - 10.1016/j.breast.2022.03.001 UR - https://doi.org/10.1016/j.breast.2022.03.001 ER -
APA
J, G., X, P., B, A., M, D. L., KH, J., A, M., H, A. A., K, G., A, A., L, H., N, T., & E, R. (2022). Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study.. Breast (Edinburgh, Scotland). https://doi.org/10.1016/j.breast.2022.03.001
Source records
- pubmed · retrieved 2026-09-26T02:24:51.577Z